CDC Warns of Resurgence of Parvovirus B19
By Physician’s Briefing Staff HealthDay Reporter
WEDNESDAY, Aug. 14, 2024 -- In a health alert issued by the U.S. Centers for Disease Control and Prevention, the agency said it has received reports of higher test positivity rates for parvovirus B19 in recent months: The proportion of people with antibodies indicating recent infection, which fell below 3 percent from 2022 to 2024, spiked to 10 percent in June.
But children between the ages of 5 and 9 years were hit particularly hard, with infection rates going from 15 percent from 2022 to 2024 to 40 percent by June 2024.
The United States is not the only country experiencing a surge in parvovirus cases: In June, the European Centre for Disease Prevention and Control reported unusually high numbers of parvovirus cases in 14 European countries during the first quarter of 2024.
Parvovirus, also known as "slapped cheek disease" for the facial rash it can cause in children, is considered common: Nearly half of Americans have detectable levels of parvovirus B19 antibodies by age 20 years, while more than 70 percent have these antibodies by the age of 40 years. People in occupations with close contact with children, such as schools and day care centers, tend to be at higher risk for infection, the CDC noted.
As with many other respiratory illnesses, social distancing measures that aimed to slow the spread of COVID-19 during the pandemic also dramatically lowered parvovirus B19 infection rates. With that came a corresponding loss of immunity to the virus, which has now translated into higher infection rates across the country.
The CDC noted it has also received reports of higher-than-expected case counts among pregnant women, including complications such as severe fetal anemia or miscarriage, and increases in a life-threatening type of anemia in people with sickle cell disease.
Many people do not have any symptoms, but if they do, there are typically two phases of illness, the CDC said. In the first phase, which begins about a week after infection, patients can develop fever, muscle aches, and malaise that last about five days. This is when people are most contagious. During the second phase of illness, children tend to develop a facial rash, followed by a body rash or joint pain. Adults often have a rash on the trunk and joint pain.
But for some people, parvovirus can cause severe complications: People with sickle cell disease or those with severely weakened immune systems may develop aplastic anemia. Among pregnant women, about 5 to 10 percent of cases can result in anemia, hydrops fetalis, or miscarriage.
Unfortunately, there is no vaccine for parvovirus and no specific treatment is indicated, the CDC said. Luckily, most infections resolve on their own with supportive care.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-15 13:15
Read more
- AHA: Rising Outdoor Temperatures Tied to Higher Risk for Atrial Fibrillation
- Avadel Pharmaceuticals Announces FDA Approval of Lumryz (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
- Child-Teacher Bond in Early Education Could Have Lasting Impact
- Being Born Preterm Tied to Lifelong Harms in Employment, Education
- 2008 to 2020 Saw More Radiologists Involved in Teaching
- Online Yoga Classes Can Ease Lower Back Pain
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions